Literature DB >> 22802316

Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.

Samuel J Klempner1, Toni K Choueiri, Eric Yee, Leona A Doyle, Detlef Schuppan, Michael B Atkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22802316     DOI： 10.1200/JCO.2011.41.0332

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Chronic active hepatitis induced by Pazopanib mimicking hypervascular liver metastases in a patient with recurrent soft tissue sarcoma: A case report.

Authors:  Ana Ezponda; Ignacio González De La Huebra; Marta Calvo; Miguel Ángel Idoate; Isabel Vivas
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

2.  Delayed nivolumab-induced hepatotoxicity during pazopanib treatment for metastatic renal cell carcinoma: An autopsy case.

Authors:  Maki Todo; Hideyuki Kondo; Taiki Hayashi; Tsukasa Masuda; Takashi Okabe; Go Kaneko; Masafumi Oyama; Suguru Shirotake; Koshiro Nishimoto
Journal:  IJU Case Rep       Date:  2019-08-03

Review 3.  Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.

Authors:  Roberto Iacovelli; Antonella Palazzo; Giuseppe Procopio; Matteo Santoni; Patrizia Trenta; Angelina De Benedetto; Silvia Mezi; Enrico Cortesi
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

4.  A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report.

Authors:  Arie J Verschoor; Fabiënne A R M Warmerdam; Tjalling Bosse; Judith V M G Bovée; Hans Gelderblom
Journal:  BMC Cancer       Date:  2018-01-22       Impact factor: 4.430

5.  Incidence and risk of regorafenib-induced hepatotoxicity.

Authors:  Bin Zhao; Hong Zhao
Journal:  Oncotarget       Date:  2017-09-20

6.  Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis.

Authors:  Franziska Paech; Jamal Bouitbir; Stephan Krähenbühl
Journal:  Front Pharmacol       Date:  2017-06-14       Impact factor: 5.810

7.  Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats.

Authors:  Chin-Tsung Ting; Yung-Yi Cheng; Tung-Hu Tsai
Journal:  Molecules       Date:  2017-06-22       Impact factor: 4.411

8.  Pazopanib-induced severe acute liver injury: A case report.

Authors:  Jin-Wook Choi; Jeong-Ju Yoo; Sang Gyune Kim; Young Seok Kim; Susie Chin
Journal:  Medicine (Baltimore)       Date:  2021-11-19       Impact factor: 1.889

9.  Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma.

Authors:  Gabriel Schwartz; Julianne O Darling; Malori Mindo; Lucia Damicis
Journal:  Target Oncol       Date:  2020-08       Impact factor: 4.493
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.